Hepatoblastoma

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 1 substance
Phase III: 1 Phase I/II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • The University Of Birmingham Academic
    IMP not specified
    2024-516110-38-00 10 countries 2018 n=292
    Recruiting

Phase I/II

1 trial
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN
    2024-518771-66-00 12 countries 2025 n=32
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 1 Phase I/II 1
The University Of Birmingham Academic 1 Phase III 1
New trials by year
2025
1
← All indication landscapes